TradeFlare's AI research teams analysed AGIO on 9 market nights between June 23, 2026 and July 30, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| July 30, 2026 | BUY | $35.01 | — / — | -2.4% | +4.7% | Anticipation of upcoming Q2 earnings. |
| July 29, 2026 | BUY | $35.99 | — / — | -9.4% | -2.9% | Upcoming Q2 earnings could provide a short-term boost if positive. |
| July 27, 2026 | BUY | $36.36 | — / — | -17.4% | -11.7% | FDA Priority Review for mitapivat. |
| July 24, 2026 | BUY | $36.28 | — / — | -17.4% | -9.0% | FDA Priority Review for Pyrukynd. |
| July 23, 2026 | BUY | $36.05 | — / — | -9.7% | -7.3% | The current market regime and the stock's fundamental and technical profiles do not support a new entry. |
| July 22, 2026 | BUY | $37.36 | — / — | -2.9% | -2.6% | FDA Priority Review for mitapivat offers potential upside. |
| July 10, 2026 | BUY | $42.79 | — / — | -3.9% | -21.7% | Positive news sentiment driven by FDA Priority Review for mitapivat in sickle cell disease. |
| June 24, 2026 | HOLD | $35.59 | — / — | +2.2% | +0.0% | Post-earnings drift signal (S9 PEAD) suggests continued upward momentum. |
| June 23, 2026 | BUY | $35.10 | — / — | +4.3% | +1.3% | The stock is in a neutral market regime and the technicals are neutral, indicating a lack of clear directional conviction. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.